Skip to content

Implementation of prehospital high Sensitive troponin and risk Stratification- validation phase

Implementation of prehospital high Sensitive troponin and risk Stratification- validation phase - IMPRESS-validation

Status
Unknown
Phases
Phase 3
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53821
Enrollment
300
Registered
2023-03-23
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute coronary syndroom chest pain

Interventions

Patients experiencing an episode of acute chest pain will call the emergency services for help. The dispatcher will send out a call to an ambulance crew. They will bring the Quidel high sensitive PO

Sponsors

Ambulancezorg Rotterdam-Rijnmond ARR
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: >= 18 age with acute chest pain suggestive of cardiac chest pain or acute coronary syndrome.

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: ST-elevation on ECG, new left bundle branch block, systolic blood pressure below 90 mmHg, tachycardia above 140 beats per minute, clinical instability, signs of acute heart failure, terminal kidney failure, pregnancy, life expectancy of less than 3 months, obvious non cardiac cause of acute chest pain, inability to provide a written informed consent or inappropriate knowledge of English or Dutch language.

Design outcomes

Primary

MeasureTime frame
Agreement of Troponin measurement between central laboratory and POCT device, numerical and as part of the HEART score.

Secondary

MeasureTime frame
Secondary objective is the ease of use, time spent performing the test.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)